Pfizer: signs agreement with Vivet Therapeutics
(CercleFinance.com) - A manufacturing agreement has been signed between Pfizer and Vivet Therapeutics, a privately owned gene therapy biotech company.
The agreement calls for Pfizer to provide clinical supply for a Phase I/II clinical trial evaluating Vivet's proprietary VTX-801.
The trial will evaluate the investigational gene therapy for the treatment of Wilson's disease, a rare and potentially fatal liver disorder.
The trial is expected to begin in early 2021. The exact terms of the agreement were not disclosed.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The agreement calls for Pfizer to provide clinical supply for a Phase I/II clinical trial evaluating Vivet's proprietary VTX-801.
The trial will evaluate the investigational gene therapy for the treatment of Wilson's disease, a rare and potentially fatal liver disorder.
The trial is expected to begin in early 2021. The exact terms of the agreement were not disclosed.
Copyright (c) 2020 CercleFinance.com. All rights reserved.